CymaBay gained more than 11% on Wednesday, following positive new 12-week and 26-week results from its ongoing phase II study of Seladelpar in patients with primary biliary cholangitis.
Original Article: CBAY Walks The Talk, MYND Explodes, NITE Sparkles, NVLN Awaits CHMP Opinion